Skip to main content

Day: December 3, 2024

Ampere and STMicroelectronics collaborate on powerbox with long term supply for silicon carbide

AMPERE AND STMICROELECTRONICS COLLABORATE ON POWERBOX WITH LONG TERM SUPPLY FOR SILICON CARBIDEMulti-year agreement between STMicroelectronics and Renault Group secures Ampere’s supply of Silicon Carbide power modules Collaboration on powerbox and cooling systems for the inverter to get the best efficiency for Ampere’s new generation electric motors Agreement aligned with Ampere’s strategy of working upstream with its partners to design the best solutions for each one of its EV technologiesBoulogne-Billancourt (France) and Geneva (Switzerland) – December 3, 2024 – Ampere, the intelligent electric vehicle (EV) pure player born from Renault Group and STMicroelectronics (NYSE: STM),  a global semiconductor leader serving customers across the spectrum of electronics applications, today announced the next step in their strategic...

Continue reading

Ampere and STMicroelectronics collaborate on powerbox with long term supply for silicon carbide

Ampere and STMicroelectronics collaborate on powerboxwith long term supply for silicon carbideMulti-year agreement between STMicroelectronics and Renault Group secures Ampere’s supply of Silicon Carbide power modules Collaboration on powerbox and cooling systems for the inverter to get the best efficiency for Ampere’s new generation electric motors Agreement aligned with Ampere’s strategy of working upstream with its partners to design the best solutions for each one of its EV technologiesBoulogne-Billancourt (France) and Geneva (Switzerland) – December 3, 2024 – Ampere, the intelligent electric EV pure player born from Renault Group and STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, today announced the next step in their strategic co-operation,...

Continue reading

Invalda INVL investor’s calendar for 2025

Invalda INVL plans to publish information to investors in 2025 in accordance with the following calendar:8 April 2025 – audited annual financial statements and annual management report.30 May 2025 – factsheet for 3 months of 2025.29 August 2025 – semi–annual report of 2025.28 November 2025 – factsheet for 9 months of 2025. Person authorised to provide additional information:Darius ŠulnisCEO of Invalda INVLE-mail darius.sulnis@invl.com

Continue reading

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 03 December 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that KIMMTRAK (tebentafusp) has been recommended for funding through the National Health Service (NHS) in England by the National Institute for Health and Care Excellence (NICE). NICE recommended KIMMTRAK within its marketing authorization for the treatment of HLA-A*02:01-positive adults...

Continue reading

Conclusion of a preliminary agreement for the acquisition of the Nõmme Südamekodu property and the establishment of a nursing home

EfTEN Capital AS and Südamekodud AS have entered into a preliminary agreement, according to which EfTEN Real Estate Fund AS will acquire a property located at Hiiu tn 42 in the Nõmme district of Tallinn through a to be established subsidiary. The aim of the agreement is to partially convert the building into a nursing home, which could accommodate up to 170 clients of Südamekodud AS in the future. The building will remain partially in use by the  North Estonia Medical Centre under a existing lease agreement.At present, no sales contract has been concluded or construction procurement has been organized. According to the intention of the parties, the sale contract under the law of obligations is planned to be concluded no later than January of next year and construction activities will begin in the second quarter of next year. Viljar Arakas Member...

Continue reading

Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

Ipsen secures exclusive global rights to develop, manufacture and commercialize BMX-502, a pre-clinical novel T cell engager (TCE) with first-in-class potentialBMX-502 is a bispecific antibody engaging MAIT cells, a subset of non-conventional T cells, and targeting the clinically validated tumor antigen GPC3 to kill cancer cellsPARIS, FRANCE; 03 December 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Biomunex Pharmaceuticals today announced an exclusive global licensing agreement for BMX-502. BMX-502 is a bispecific antibody that engages and activates a subset of cytotoxic T cells called Mucosal-Associated Invariant T cells (MAIT cells) and targets the GPC3 tumor antigen, to kill cancer cells. GPC3 is a clinically validated target, highly expressed across several cancer types.1 MAIT cells are present throughout the body, highly...

Continue reading

Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

Antibody levels remained high at 96% seroresponse in line with the two-year persistence data  This long-lasting antibody persistence was comparable in older (65+) and younger adultsSaint-Herblain (France), December 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine IXCHIQ®. The results are in line with Valneva’s expectations for this vaccine, confirming a strong and long-lasting antibody persistence across all age groups investigated. The three-year persistence data are also in line with positive twelve-month and two-year persistence data the Company reported in December 20221 and 20232, respectively. Among the 278 healthy adults still enrolled in the trial, 96% maintained...

Continue reading

Feintool reorganizes the production of rotors and stators for electric motors in Europe

This is an ad hoc announcement pursuant to Article 53 of the Listing Rules (LR) of the SIX Exchange Regulation AG The challenging developments in the European automotive sector are characterized by a very demanding market environment. Manufacturers and suppliers are adapting their production and business models. In addition, the industrial business is still not recovering. Feintool reviews its strategic capacity planning on a regular basis and is planning a change in production capacity allocation in Europe. The Feintool Group is facing major challenges in its European business for electric motors, due to several factors: political uncertainty in relation to electromobility and the transition to renewable energies, as well as an economic downturn in the industrial business. These unfavorable conditions have led to a slowdown or decline...

Continue reading

This Thanksgiving, Tims China Spreads Warmth with Pay-It-Forward “Timsgiving” Campaign

SHANGHAI, Dec. 02, 2024 (GLOBE NEWSWIRE) — Over the past week, Tims China’s coffee shops across the country have been filled with the spirit of gratitude and celebration, spurred on by the inaugural “Timsgiving” campaign.   “Sharing kindness and paying it forward in our communities is a Tim Hortons tradition. This Thanksgiving, we were thrilled to introduce the ‘Timsgiving’ pay-it-forward campaign in China, encouraging our guests to enjoy and share a free coffee,” said Yongchen Lu, CEO of Tims China. “In the end, we saw 1,500 people forward coffee from one customer to the next with the longest chains being 30 customers in a row. We hope this initiative brought about many heartwarming moments and inspired others to spread warmth and goodwill.” In one heartwarming example at a Tims store at Central China Normal University, a college...

Continue reading

HashiCorp awarded a 2024 AWS partner award

HashiCorp recognized as Collaboration Partner of the Year winner, helping to ensure AWS customers do cloud right with Infrastructure and Security Lifecycle Management LAS VEGAS, Dec. 02, 2024 (GLOBE NEWSWIRE) — HashiCorp (NASDAQ: HCP), The Infrastructure Cloud™ Company, is honored to announce it is a recipient of a 2024 Geography and Global AWS Partner Award for Collaboration Partner of the Year – North America. The award recognizes HashiCorp as a partner organization that collaborates with other AWS Partners on solving customer challenges and on the ability to deliver valuable customer solutions based on services and technology offered across multiple AWS Partners. The HashiCorp Cloud Platform (HCP) provides Infrastructure Lifecycle Management (ILM) and Security Lifecycle Management (SLM) capabilities that enable...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.